Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic
liver disease. Although there are no approved therapies, major breakthroughs, which will be
reviewed here, have paved the way for future therapeutic successes. The unmet medical
need in NASH is no longer disputed, and progress in the understanding of its pathogenesis
has resulted in the identification of many pharmacological targets. Key surrogate outcomes …